questionsmedicales.fr
Comportement et mécanismes comportementaux
Pulsion
Besoin impérieux
Besoin impérieux : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Craving
Évaluation clinique
Questionnaires
Entretien clinique
Troubles mentaux
Addiction
DSM-5
Troubles liés à des substances
Échelles de mesure
Craving
Symptômes
5
Symptômes physiques
Palpitations
Stimuli environnementaux
Craving
Comportement compulsif
Craving
Prévention
5
Éducation
Gestion du stress
Programmes de sensibilisation
Craving
Compétences d'adaptation
Prévention
Groupes de soutien
Craving
Déclencheurs
Gestion du craving
Traitements
5
Thérapies comportementales
Médicaments
Thérapie cognitivo-comportementale
Craving
Soutien social
Gestion du craving
Méditation
Pleine conscience
Complications
5
Troubles de santé mentale
Comportements à risque
Santé physique
Comportements nuisibles
Relations personnelles
Craving
Problèmes juridiques
Comportements impulsifs
Facteurs de risque
5
Antécédents familiaux
Stress
Environnement social
Craving
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Besoin impérieux : Questions médicales les plus fréquentes",
"headline": "Besoin impérieux : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Besoin impérieux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-02",
"dateModified": "2025-02-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Besoin impérieux"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pulsion",
"url": "https://questionsmedicales.fr/mesh/D004328",
"about": {
"@type": "MedicalCondition",
"name": "Pulsion",
"code": {
"@type": "MedicalCode",
"code": "D004328",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "F01.658.293"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Besoin impérieux",
"alternateName": "Craving",
"code": {
"@type": "MedicalCode",
"code": "D066249",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Michael A Sayette",
"url": "https://questionsmedicales.fr/author/Michael%20A%20Sayette",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."
}
},
{
"@type": "Person",
"name": "Kathleen A Garrison",
"url": "https://questionsmedicales.fr/author/Kathleen%20A%20Garrison",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA."
}
},
{
"@type": "Person",
"name": "Matthew C Enkema",
"url": "https://questionsmedicales.fr/author/Matthew%20C%20Enkema",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, University of Washington."
}
},
{
"@type": "Person",
"name": "Kevin A Hallgren",
"url": "https://questionsmedicales.fr/author/Kevin%20A%20Hallgren",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of Washington."
}
},
{
"@type": "Person",
"name": "Mary E Larimer",
"url": "https://questionsmedicales.fr/author/Mary%20E%20Larimer",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of Washington."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Adjuvant Topical Interferon Alpha 2b for the Treatment of Monkeypox Ocular Manifestations.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37643461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003360"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pegylated Interferon Alpha 2a for the Treatment of Ocular Surface Squamous Neoplasia.",
"datePublished": "2022-07-04",
"url": "https://questionsmedicales.fr/article/36107845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003086"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interferon-alpha regulates expression of lncRNA MALAT1 and interferon-stimulated genes, as well as chemokine production, in primary Sjögren's syndrome.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36189916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/ggkc9t"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis.",
"datePublished": "2023-01-26",
"url": "https://questionsmedicales.fr/article/36776844",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1069894"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigation of an anticancer activity of combination of interferon-alpha and gemcitabine on pancreatic cancer cells.",
"datePublished": "2024-01-22",
"url": "https://questionsmedicales.fr/article/39412913",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/jcrt.jcrt_138_23"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Comportement et mécanismes comportementaux",
"item": "https://questionsmedicales.fr/mesh/D001520"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pulsion",
"item": "https://questionsmedicales.fr/mesh/D004328"
},
{
"@type": "ListItem",
"position": 4,
"name": "Besoin impérieux",
"item": "https://questionsmedicales.fr/mesh/D066249"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Besoin impérieux - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Besoin impérieux",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Besoin impérieux",
"description": "Comment diagnostiquer un besoin impérieux ?\nQuels outils sont utilisés pour le diagnostic ?\nLe besoin impérieux est-il un trouble mental ?\nQuels critères DSM sont liés au besoin impérieux ?\nPeut-on mesurer l'intensité du craving ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-alpha#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Besoin impérieux",
"description": "Quels sont les symptômes du besoin impérieux ?\nLe besoin impérieux peut-il causer de l'anxiété ?\nY a-t-il des symptômes physiques associés ?\nLe craving est-il constant ou intermittent ?\nComment le craving affecte-t-il le comportement ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-alpha#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Besoin impérieux",
"description": "Comment prévenir le besoin impérieux ?\nLes programmes de sensibilisation sont-ils efficaces ?\nLe développement de compétences aide-t-il ?\nLes groupes de soutien sont-ils utiles ?\nLa gestion des déclencheurs est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-alpha#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Besoin impérieux",
"description": "Quels traitements sont efficaces contre le craving ?\nLa thérapie cognitivo-comportementale aide-t-elle ?\nLes médicaments peuvent-ils réduire le craving ?\nLe soutien social est-il important dans le traitement ?\nY a-t-il des approches alternatives au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-alpha#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Besoin impérieux",
"description": "Quelles complications peuvent survenir avec le craving ?\nLe craving peut-il mener à des addictions ?\nY a-t-il des risques physiques associés au craving ?\nLe besoin impérieux affecte-t-il les relations ?\nLe craving peut-il entraîner des problèmes juridiques ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-alpha#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Besoin impérieux",
"description": "Quels sont les facteurs de risque du craving ?\nLe stress augmente-t-il le risque de craving ?\nLes troubles mentaux sont-ils des facteurs de risque ?\nL'environnement social influence-t-il le craving ?\nLes habitudes de vie jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D066249?mesh_terms=Interferon-alpha#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un besoin impérieux ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des symptômes et des antécédents du patient."
}
},
{
"@type": "Question",
"name": "Quels outils sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires standardisés et des entretiens cliniques sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "Le besoin impérieux est-il un trouble mental ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être associé à des troubles comme l'addiction ou les troubles alimentaires."
}
},
{
"@type": "Question",
"name": "Quels critères DSM sont liés au besoin impérieux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères DSM-5 pour les troubles liés à des substances incluent le craving."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'intensité du craving ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des échelles de mesure spécifiques évaluent l'intensité du craving."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du besoin impérieux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une envie intense, agitation, et parfois des symptômes physiques."
}
},
{
"@type": "Question",
"name": "Le besoin impérieux peut-il causer de l'anxiété ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le craving peut entraîner une anxiété significative chez les individus concernés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la transpiration ou des palpitations peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le craving est-il constant ou intermittent ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être intermittent, souvent déclenché par des stimuli environnementaux."
}
},
{
"@type": "Question",
"name": "Comment le craving affecte-t-il le comportement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut mener à des comportements compulsifs pour satisfaire l'envie."
}
},
{
"@type": "Question",
"name": "Comment prévenir le besoin impérieux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'éducation, la gestion du stress et le soutien social."
}
},
{
"@type": "Question",
"name": "Les programmes de sensibilisation sont-ils efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à informer sur les risques et à réduire le craving."
}
},
{
"@type": "Question",
"name": "Le développement de compétences aide-t-il ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, développer des compétences d'adaptation peut réduire le risque de craving."
}
},
{
"@type": "Question",
"name": "Les groupes de soutien sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils offrent un environnement de soutien pour partager des expériences."
}
},
{
"@type": "Question",
"name": "La gestion des déclencheurs est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, identifier et gérer les déclencheurs peut prévenir le craving."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre le craving ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies comportementales et les médicaments peuvent aider à réduire le craving."
}
},
{
"@type": "Question",
"name": "La thérapie cognitivo-comportementale aide-t-elle ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est efficace pour modifier les pensées et comportements liés au craving."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils réduire le craving ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments, comme les antidépresseurs, peuvent diminuer le craving."
}
},
{
"@type": "Question",
"name": "Le soutien social est-il important dans le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le soutien social joue un rôle crucial dans la gestion du craving."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches alternatives au traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la méditation et la pleine conscience peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le craving ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles de santé mentale et des comportements à risque."
}
},
{
"@type": "Question",
"name": "Le craving peut-il mener à des addictions ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un besoin impérieux non traité peut évoluer vers une addiction sévère."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques physiques associés au craving ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le craving peut entraîner des comportements nuisibles à la santé physique."
}
},
{
"@type": "Question",
"name": "Le besoin impérieux affecte-t-il les relations ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut nuire aux relations personnelles et professionnelles."
}
},
{
"@type": "Question",
"name": "Le craving peut-il entraîner des problèmes juridiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des comportements impulsifs liés au craving peuvent causer des problèmes juridiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du craving ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le stress et l'environnement social sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "Le stress augmente-t-il le risque de craving ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress est un facteur majeur qui peut intensifier le besoin impérieux."
}
},
{
"@type": "Question",
"name": "Les troubles mentaux sont-ils des facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme l'anxiété et la dépression augmentent le risque de craving."
}
},
{
"@type": "Question",
"name": "L'environnement social influence-t-il le craving ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement social négatif peut exacerber le besoin impérieux."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie malsaines peuvent augmenter le risque de craving."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Publications dans "Besoin impérieux" :
3 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Publications dans "Besoin impérieux" :
3 publications dans cette catégorie
Affiliations :
Department of Psychology, University of Washington.
Publications dans "Besoin impérieux" :
3 publications dans cette catégorie
Affiliations :
Department of Psychiatry, University of Washington.
Publications dans "Besoin impérieux" :
3 publications dans cette catégorie
Affiliations :
Department of Psychiatry, University of Washington.
Publications dans "Besoin impérieux" :
3 publications dans cette catégorie
Affiliations :
Yale University, New Haven, CT 06510, United States. Electronic address: hedy.kober@yale.edu.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Secretaría de Salud de la Ciudad de México, Ciudad de México. México.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States. Electronic address: lararay@psych.ucla.edu.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Psychology, School of Medical Sciences, Universidad Nacional de Asunción, San Lorenzo 111454, Paraguay.
Regional Institute of Health Research, Universidad Nacional de Caaguazú, Coronel Oviedo 050106, Paraguay.
School of Health Sciences, Universidad Sudamericana, Pedro Juan Caballero 130112, Paraguay.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Experimental Medicine, Medical School, University of Foggia, 71100 Foggia, Italy.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Hospital Sírio-Libanês, São Paulo 01308-050, Brazil.
Department of Psychiatry, Medical School, University of São Paulo, São Paulo 05403-903, Brazil.
Department of Neuroscience, Medical School, FMABC University Center, Santo André 09060-870, Brazil.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychology, Pacific University.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: cberge21@jhmi.edu.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Publications dans "Besoin impérieux" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Publications dans "Besoin impérieux" :
The aim of this study was to report a case of ocular Mpox that responded favorably to treatment with topical interferon and oral doxycycline....
This is a case report of a previously healthy 24-year-old woman who developed a pustular rash, headache, fever, arthralgia, sore throat, and asthenia 3 weeks before attending to our clinic. Her main c...
Mpox with ocular manifestations diagnosis was confirmed by real-time quantitative reverse transcription polymerase chain reaction assay (qRT-PCR) testing; samples were taken from corneal, conjunctival...
Alternative and efficacious treatment options for Mpox ocular manifestations are needed to prevent further disease progression and sequelae in countries with no access to the gold-standard therapy. To...
The purpose of this study was to introduce the initial experience in the use of topical pegylated interferon alpha 2a (PegIFN-α-2a) for ocular surface squamous neoplasia (OSSN)....
A retrospective medical record review of 8 eyes of 8 patients diagnosed with OSSN and treated with PegIFN-α-2a was performed. All cases were diagnosed of noninvasive OSSN both clinically and histologi...
In all 8 cases, topical PegIFN-α-2a was well-tolerated and did not lead to discomfort or any adverse side effects. It resulted in reduction in lesion size and extent in all cases and complete resoluti...
Topical PegIFN-α-2a might be an effective and safe treatment option for noninvasive OSSN....
This study aimed to explore the contribution of interferon-alpha (IFN-α) to MALAT1 expression in primary Sjögren's syndrome (pSS)....
Peripheral blood mononuclear cells (PBMC) from pSS patients and healthy blood donors were stimulated with recombinant human IFN-α, and the expression levels of MALAT1 and several interferon-stimulated...
In this work, we found that MALAT1 expression levels were increased in IFN-α-stimulated PBMC from pSS patients and healthy controls. As expected, ISG expression levels and interferon-regulated chemoki...
Our data provide insights into the abnormal IFN-α-mediated regulation of the lncRNA MALAT1 in pSS. Based on an unusually high capacity of PBMC to express ISG and to produce interferon-responsive chemo...
IFN-α intervention may block SARS-CoV-2 replication and normalize the deregulated innate immunity of COVID-19....
This meta-analysis aimed to investigate the efficacy of interferon IFN-α-containing regimens when treating patients with moderate-to-severe COVID-19....
PubMed, SCOPUS, and ClinicalTrials.gov were searched from inception to 15 January 2022. A systematic literature search was conducted by applying relevant terms for 'COVID-19' and 'interferon-α'. The p...
Eleven studies are enclosed in the meta-analysis. No significant difference in the all-cause mortality rate was found between the study and control groups (OR 0.2; 95% CI 0.05-1.2; I...
Thus, IFN-α does not benefit the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital....
www.crd.york.ac.uk/prospero, identifier (CRD42022374589)....
Pancreatic ductal adenocarcinoma (PDAC) is still a clinical challenge due to its deteriorated prognosis. Therefore, new combination chemotherapeutic approaches are of research interest. In this work, ...
Surfactants are commonly used in biopharmaceutical formulations to stabilize proteins against aggregation. However, the choice of a suitable surfactant for a particular protein is decided mostly empir...
The addition of interferon to tyrosine kinase inhibitors (TKIs), to improve deep molecular response (DMR) and potentially treatment-free remission (TFR) rates in chronic-phase chronic myeloid leukaemi...
Human interferon alpha 2a (IFNα2a) is a secreted glycoprotein that exerts a wide spectrum of biological effects, such as triggering of antiviral, antitumor and immunosuppressive responses. IFNα2a is u...
The adaptive immune response to viral infections features the antigen-driven expansion of CD8+ T cells. These cells are widely recognized for their cytolytic activity that is mediated through the secr...
Natural killer (NK) cells mount an immune response against hepatitis C virus (HCV) infection and can be activated by several cytokines, including interleukin-2 (IL-2), IL-15, and interferon-alpha (IFN...